THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, March 05, 2025
Immunotherapy targets cancer cells, offers fewer side effects, personalized treatment, and potential cures, revolutionizing cancer care and outcomes.
Fremont, CA: Immunotherapy has transformed oncology. It may treat difficult-to-reach malignancies, create long-lasting effects, and target cancer cells specifically. Immunotherapy is a viable treatment option for many cancer patients because of its advantages, which include fewer side effects, individualized treatments, and the possibility of a cure.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
One of the primary benefits of immunotherapy is that it selectively targets cancer cells while sparing healthy tissues. Traditional treatments like chemotherapy work by attacking rapidly dividing cells, but they often damage healthy cells as well, leading to significant side effects. In contrast, immunotherapy works by stimulating or enhancing the immune system's ability to distinguish between cancerous and non-cancerous cells, allowing for a more focused attack on the tumor. This precision lowers the chance of collateral damage to healthy tissues and minimizes the risk of long-term side effects.
Certain cancers that are difficult to treat with traditional methods, such as melanoma, lung cancer, and some types of leukemia and lymphoma, have shown promising responses to immunotherapy. Immune checkpoint inhibitors, a form of immunotherapy, have revolutionized the treatment of cancers that were once considered untreatable. By blocking the immune system's brakes, these therapies allow immune cells to attack and destroy tumors more effectively.
For instance, melanoma, once a notoriously difficult cancer to treat, has seen remarkable improvements in survival rates with immune checkpoint inhibitors. Other cancers like renal cell carcinoma and non-small cell lung cancer have also shown promising outcomes.
Immunotherapy's side effects are often less severe than those caused by chemotherapy or radiation. Chemotherapy, for example, commonly causes nausea, hair loss, and a weakened immune system, while radiation therapy can result in fatigue and damage to surrounding organs. Immunotherapy typically causes fewer and less severe side effects, such as mild flu-like symptoms or skin rashes, which are more manageable. Some immunotherapies, like monoclonal antibodies, have fewer systemic effects and specifically target cancer cells, which can minimize the damage to healthy organs.
Immunotherapy has introduced a new era of personalized medicine in cancer care. Researchers are continually developing diagnostic tools that find which patients are more likely to profit from specific immunotherapies based on their genetic makeup or the genetic profile of their cancer. This tailored approach assures patients receive the most appropriate treatment for their particular condition, increasing the likelihood of a successful outcome.
For example, certain cancers have specific genetic mutations or molecular markers that make them more responsive to immunotherapies, such as checkpoint inhibitors or CAR-T cell therapy. Identifying these biomarkers enables clinicians to select treatments that are more likely to yield positive results.
Immunotherapy offers the exciting possibility of not just controlling cancer but potentially curing it. Some patients who have received immunotherapy have experienced complete remission, where no signs of cancer remain in the body.
More in News